

522-1768

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.5)

10/009808

TRANSMITTAL LETTER TO THE UNITED STATES

DESIGNATED/ELECTED OFFICE (DO/EO/US)

CONCERNING A FILING UNDER 35 U.S.C. 371

INTERNATIONAL APPLICATION NO.

PCT/BE00/00066

INTERNATIONAL FILING DATE

June 19, 2000

PRIORITY DATE CLAIMED

June 17, 1999

TITLE OF INVENTION

Functional Poly-Alpha-Aminoacid Derivatives Useful for the Modificaiton of Biologically Active Materials and Their Use

APPLICANT(S) FOR DO/EO/US

Etienne Honore Schacht and Veska Toncheva

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31)
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b ☒ has been communicated by the International Bureau
 - c ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a ☐ is attached hereto.
 - b ☐ has been previously submitted under 35 U.S.C. 154(d)(4)
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a ☐ are attached hereto (required only if not communicated by the International Bureau)
 - b ☒ have been communicated by the International Bureau
 - c ☐ have not been made, however, the time limit for making such amendments has NOT expired.
 - d ☐ have not been made and will not be made
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4))
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5))
11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A copy of the International Search Report (PCT/ISA/210)

Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98
14. ☐ An assignment document for recording A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included
15. ☒ A **FIRST** preliminary amendment
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter 2 and 35 U.S.C. 1.821 - 1.825
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☐ Certificate of Mailing by Express Mail
23. ☐ Other items or information

U.S. APPLICATION NO (IF KNOWN, SEE 37 CFR 1.5)		INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER	
10,009808		PCT/BE00/00066		522-1768	
24. The following fees are submitted				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :					
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO				\$1040.00	
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO				\$890.00	
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO				\$740.00	
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)				\$710.00	
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)				\$100.00	
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$890.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e))				\$0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	22 - 20 =	2	x \$18 00	\$36.00	
Independent claims	7 - 3 =	4	x \$84 00	\$336.00	
Multiple Dependent Claims (check if applicable).			<input type="checkbox"/>	\$0.00	
TOTAL OF ABOVE CALCULATIONS =				\$1,262.00	
<input checked="" type="checkbox"/> Applicant claims small entity status See 37 CFR 1.27) The fees indicated above are reduced by 1/2				\$631.00	
SUBTOTAL =				\$631.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				\$0.00	
TOTAL NATIONAL FEE =				\$631.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)) The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).			<input type="checkbox"/>	\$0.00	
TOTAL FEES ENCLOSED =				\$631.00	
				Amount to be: refunded	\$
				charged	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$631.00 to cover the above fees is enclosed.					
b. <input type="checkbox"/> Please charge my Deposit Account No _____ in the amount of _____ to cover the above fees A duplicate copy of this sheet is enclosed					
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 12-0913 A duplicate copy of this sheet is enclosed.					
d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
William M. Lee, Jr. LEE, MANN, SMITH, MCWILLIAMS SWEENEY & OHLSON P. O. Box 2786 Chicago, IL 60690-2786			SIGNATURE William M. Lee, Jr. NAME 26,935 REGISTRATION NUMBER 12-07-01 DATE		

PTO/PCT Rec'd 12 APR 2002

522-1768

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE THE APPLICATION OF)

Schacht et al.)

SERIAL NO.: 10/009,808)


FILED: December 7, 2001)

FOR: FUNCTIONAL POLY-ALPHA-)
 AMINOACID DERIVATIVES USEFUL)
 FOR THE MODIFICATION OF)
 BIOLOGICALLY ACTIVE MATERIALS)
 AND THEIR USE)

) Examiner:

) Group Art Unit No.

I hereby certify that this correspondence is being deposited with
 the United States Postal Service as first class mail in an
 envelope addressed to "Assistant Commissioner of Patents,
 Washington, D C 20231" on April 1, 2002

Name of person signing Jennifer J. RamirezSignature **PRELIMINARY AMENDMENT**

Honorable Commissioner of
 Patents and Trademarks
 Washington, D.C. 20231

Dear Sir:

Appended hereto is a copy of the un-entered amendment submitted with this application.

It is requested that the application be amended as follows:

IN THE CLAIMS:


Cancel claims 1 through 35 without prejudice, and substitute new claim 36 - 57 as set
 forth in the attached "Amendment Accompanying Application".

Remarks

With the proper cancellation of all claims, it is believed that the proper fees have now been tendered and claims 36 - 57 can now be entered in place of claims 1 through 35 of the international application. Should any of the original claims remain, that is unintended, and it is requested that all claims of the international application be cancelled and new claims 36 - 57 substituted in their place.

April 1, 2002

Respectfully submitted,

A handwritten signature in dark ink, appearing to read "William M. Lee, Jr.", is written over a horizontal line.

William M. Lee, Jr.
Registration No. 26,935
Lee, Mann, Smith, McWilliams,
Sweeney & Ohlson
P.O. Box 2786
Chicago, Illinois 60690-2786
(312) 368-6620
(312) 368-0034 (fax)

IN RE THE APPLICATION OF

Schatch et al

SERIAL NO.:

FILED:

FOR: FUNCTIONAL POLY-ALPHA-AMINOACID DERIVATIVES USEFUL FOR THE MODIFICATION OF BIOLOGICALLY ACTIVE MATERIALS AND THEIR USE

) Examiner:

) Group Art Unit:

Honorable Commissioner for Patents
Washington, D.C. 20231


Dear Sir:

The present application is the national filing of International Application No. PCT/BE00/00066. Before calculation of the national filing fee for the United States, it is requested that the application be amended as follows:

In the claims:

Cancel claims 1 - 22 without prejudice, and substitute new claims 36 - 57 as follows:

36. A linear monofunctional or multifunctional poly- α -amino-acid derivative having at least glutamic or aspartic or serinic repeating units in the polymer backbone, the said glutamic or aspartic or serinic repeating units having the formula:






wherein:

- R is defined as $-(CH_2)_n-CO-OR_1$ or $-(CH_2)_n-CO-NHR_2$ or CH_2OH .

- n is 1 or 2,
 - R₁ is selected from hydrogen, C₁₋₂₀ alkyl, polyhaloC₁₋₆alkyl, arylC₁₋₆ alkyl and heteroarylC₁₋₆ alkyl, and
 - R₂ is C₁₋₆ alkyl substituted with at least one alcohol group, characterized in additionally having a functional group at one or both ends of the polymer backbone, the said functional end group(s) being other than alcohol.
37. A linear multifunctional poly- α -amino-acid derivative according to claim 36, wherein the said functional end group is selected from the group consisting of amine, carboxyl, ester, carbonate, thiol, thiol precursor, thioisocyanate, thiocarbonate, urea, thiourea, aldehyde, acetal, N-carboxyanhydride, oxycarbonyl, maleimide and any vinyl group suitable for radical, anionic or cationic polymerization.
38. A linear multifunctional poly- α -amino-acid derivative according to claim 36, having a functional group at both ends of the polymer backbone, and additionally having a single functional group as a side group.
39. A linear poly- α -amino-acid derivative according to claim 36, additionally comprising repeating units of one or more comonomer(s) copolymerizable with the α -amino-acid sequence containing glutamic or aspartic or serinic repeating units.
40. A linear poly- α -amino-acid derivative according to claim 36, additionally comprising repeating units of one or more comonomer(s) copolymerizable with the α -amino-acid sequence containing glutamic or aspartic or serinic repeating units, wherein the said co-monomer is selected from the group consisting of any naturally-occurring α -amino-acid other than glutamic acid, aspartic acid and serine and polymer

blocks or sequences derived from ethylene oxide or propylene oxide or polyhydroxyalkanoates.

41. A linear poly- α -amino-acid derivative according to claim 36, being multifunctional and having any of the following formulae:



W







W

wherein:

- R is as defined in claim 36,
- x or, where applicable, x + x' range from 2 to 2,000,
- each of V and W independently represent a functional group,
- A is at least a co-monomer copolymerizable with the α -amino-acid sequence containing glutamic or aspartic or serinic repeating units,
- y ranges from 0 to 500,
- T is a spacing unit selected from lysine and ornithine, and
- V' is a non-reactive end group.

42. A linear poly- α -amino-acid derivative according to claim 36, being monofunctional and having any of the following formulae:





W

wherein:

- R is as defined in claim 36,
- x or, where applicable, x + x' range from 2 to 2,000, and
- each of V and W independently represent a functional group,
- A is at least a co-monomer copolymerizable with the α -amino-acid sequence containing glutamic or aspartic or serinic repeating units,
- y ranges from 0 to 500,
- T is a spacing unit selected from lysine and ornithine, and
- V' and W' are non-reactive end groups.

43. A linear poly- α -amino-acid derivative according to claim 36, having at least one protective end group and being represented by the following formulae:




wherein:

- R is $-(CH_2)_n-CO-NHR_2$,
- R_2 and n are as defined in claim 36,
- x ranges from 2 to 2,000,
- X_1 is $-R_4-Z_1-A_1$,
- each of R_3 and R_4 is independently selected from $(CH_2)_m$, arylene, C_{1-6} alkylarylene and aryl C_{1-6} alkylene,
- m is from 2 to 20,
- Y_1 is $-Z_2-A_2$,
- X_2 is $-R_4-Z_3-A_3$ or $-O-R_4-Z_3-A_3$,
- Y_2 is $-Z_4-A_4$,
- each of Z_1, Z_2, Z_3 and Z_4 is independently selected from NH, O, S, C(O)O, C(S)O, CO, CS, $-OCH-O-$ and $C=N-R_5$,
- each of A_1, A_2, A_3 and A_4 is a protective group suitable for Z_1, Z_2, Z_3

and Z₄ respectively, and

- R₅ is selected from hydrogen, C₁₋₆ alkyl, aryl and C₁₋₆ alkylaryl, heteroaryl and C₁₋₆ alkylheteroaryl.


44. A linear poly-α-amino-acid derivative according to claim 36, being represented by the formula:




wherein:

- X₁ is - R₄ - Z₁ - A₁,
- R₄ is selected from (CH₂)_m, arylene, C₁₋₆ alkylarylene and arylC₁₋₆ alkylene,
- x ranges from 2 to 2,000,
- R is defined as -(CH₂)_n- CO - OR₁,
- R₁ and n are as defined in claim 36,
- Z₁ is selected from NH, O, S, C(O)O, C(S)O, CO, CS, -OCH-O- and C = N - R₅,
- A₁ is a protective group suitable for Z₁, and
- R₅ is selected from hydrogen, C₁₋₆ alkyl, aryl and C₁₋₆ alkylaryl, heteroaryl and C₁₋₆ alkylheteroaryl.

45. A linear poly-α-amino-acid derivative according to claim 36, being represented by any of the respective formulae:



(X), and



(XI), wherein:

- R is $-(CH_2)_n-CO-NHR_2$,
- R_2 and n are as defined in claim 36,
- x ranges from 2 to 2,000;
- X_1 is $-R_4-Z_1-D_1$,
- each of R_3 and R_4 is independently selected from $(CH_2)_m$, arylene, C_{1-6} alkylarylene and aryl C_{1-6} alkylene,
- m is from 2 to 20,
- each of R_3-Y_1 and R_3-Y_2 may be a group including a vinyl terminal moiety,
- X_2 is $-R_4-Z_3-D_3$,
- each of Z_1 , Z_2 , Z_3 and Z_4 is independently selected from NH, O, S, $C(O)O$, $C(S)O$, CO, CS, $-OCH-O-$ and $C=N-R_5$,
- each of D_1 , D_2 , D_3 and D_4 is independently selected from hydrogen, aryl, heteroaryl, succinimidyl, vinyl, C_{1-6} alkylcarbonyl,
- each of Z_1-D_1 , Z_2-D_2 , Z_3-D_3 and Z_4-D_4 may be independently selected from maleimidyl, disulfide, α -haloacetoxy and C_{1-6} alkyloxy-methylsulfide, and
- R_5 is selected from hydrogen, C_{1-6} alkyl, aryl and C_{1-6} alkylaryl, heteroaryl and C_{1-6} alkylheteroaryl.

46. A process for making a linear monofunctional or multifunctional poly- α -amino-acid derivative having at least glutamic or aspartic or serinic repeating units in the polymer backbone and additionally having a functional group at one or both ends of the polymer backbone, the said functional end group(s) being other than alcohol, including a step comprising polymerizing a monomer or mixture of monomers comprising at least the N-carboxy anhydride of an amino-acid selected from glutamic acid, aspartic acid, serine and oxygen-protected serine in the presence of an effective amount of a multifunctional initiator containing at least one primary amino group and further containing at least another functional group selected from maleimide, thioisocyanate,

thiocarbonate, urea, thiourea, aldehyde, acetal, oxycarbonyl, vinyl, ester, carbonate, thiol precursor, protected amine and protected carboxylic acid and/or in the presence of an effective amount of a bi-functional terminating reagent.

47. A process according to claim 46, further including aminolysis of the pending group of the glutamic, aspartic or serinic repeating unit derived from glutamic acid, aspartic acid or serine by means of an effective amount of an amino-alcohol, in the presence of an effective amount of a reaction promoter.
48. A process for making a linear monofunctional or multifunctional poly- α -amino-acid derivative having at least glutamic or aspartic or serinic repeating units in the polymer backbone and additionally having a functional group at one or both ends of the polymer backbone, the said functional end group(s) being other than alcohol, including:
 - a first step of N-acylating part of an α -amino-acid selected from glutamic acid, aspartic acid and serine, then separately treating the N-acylated α -amino-acid and the remaining part of the said α -amino-acid in order to form a mixture of the corresponding N-carboxy anhydrides, and
 - a second step of copolymerizing the said mixture of N-carboxy anhydrides in the presence of an initiator.
49. A process according to claim 48, wherein the N-carboxy anhydride terminated polymer obtained in the second step is reacted with a reagent having the formula $H_2N - R_3 - Y_2$, wherein:
 - R_3 is selected from $(CH_2)_m$, arylene, C_{1-6} alkylarylene and aryl C_{1-6} alkylene,

- Y_2 is $-Z_4-A_4$,
 - Z_4 is selected from NH, O, S, C(O)O, C(S)O, CO, CS, -OCH-O- and $C \equiv N-R_5$,
 - A_4 is a protective group suitable for Z_4 , and
 - R_5 is selected from hydrogen, C_{1-6} alkyl, aryl and C_{1-6} alkylaryl, heteroaryl and C_{1-6} alkylheteroaryl.
50. A biodegradable article containing a copolymer comprising at least a moiety derived from a linear monofunctional or multifunctional poly- α -amino-acid derivative having at least glutamic or aspartic or serinic repeating units in the polymer backbone and additionally having a functional group at one or both ends of the polymer backbone, the said functional end group(s) being other than alcohol, provided that the said functional end group(s) is an unsaturated group.
51. A poly- α -amino-acid derivative according to claim 36, containing a L-amino-acid sequence and being enzymatically degradable.
52. A poly- α -amino-acid derivative according to claim 36, containing a D-amino-acid sequence, being non-degradable, for the surface modification of a biomaterial.
53. The product of coupling a biomolecule with a linear monofunctional or multifunctional poly- α -amino-acid derivative having at least glutamic or aspartic or serinic repeating units in the polymer backbone and additionally having a functional group at one or both ends of the polymer backbone, the said functional end group(s) being other than alcohol.
54. The product of claim 53, wherein the said biomolecule is selected from the group consisting of therapeutic agents, prophylactic agents,

diagnostic agents, proteins, peptides, hormones, antibodies and fragments thereof, oligonucleotides, plasmids, DNAs, interleukins, interferons and enzymes and fragments thereof.

55. A synthetic polymer for a polymer-based carrier vehicle or vector for delivery of DNA or other nucleic acid material to target cells in a biological system, comprising a linear monofunctional or multifunctional poly- α -amino-acid derivative having at least glutamic or aspartic or serinic repeating units in the polymer backbone and additionally having a functional group at one or both ends of the polymer backbone, the said functional end group(s) being other than alcohol.
56. A synthetic polymer for a polymer-based carrier vehicle or vector according to claim 55, further comprising a synthetic vector component such as polyethyleneimine, poly-L-lysine, a star-shaped dendrimer or chitosan.
57. A method of treatment of a patient in need of such treatment, comprising administration to said patient of a biologically-active ingredient modified by or a nucleic acid material carried by a polymer system comprising a linear monofunctional or multifunctional poly- α -amino-acid derivative having at least glutamic or aspartic or serinic repeating units in the polymer backbone and additionally having a functional group at one or both ends of the polymer backbone, the said functional end group(s) being other than alcohol.

REMARKS


The above amendments are being made in order to eliminate multiple dependency and improper multiple dependency before calculation of the national filing fee for the United States. Should any multiple dependency remain, that is unintended, and the Patent and Trademark Office is requested

to cancel any remaining multiple dependent claims without prejudice before calculation of the filing fee.

Examination of the application on its merits is awaited.

Dated: December 7, 2001

Respectfully submitted,



William M. Lee, Jr.
Registration No. 26,935

Lee, Mann, Smith, McWilliams,
Sweeney & Ohlson
P.O. Box 2786
Chicago, IL 60690-2786
(312) 368-1300
(312) 368-0034 (Fax)

10/009808

FUNCTIONAL POLY- α -AMINOACID DERIVATIVES USEFUL FOR THE MODIFICATION OF BIOLOGICALLY
ACTIVE MATERIALS AND THEIR APPLICATION

The present invention relates to the preparation of novel functional poly-
5 α -amino-acid derivatives which are useful namely for the modification of
biomolecules and the surface modification of biomaterials. It also relates to
modified synthetic vectors useful for gene delivery which are obtainable from
the said novel functional poly- α -amino-acid derivatives. The invention
additionally relates to antibodies and to various therapeutic agents modified by
10 the said novel functional poly- α -amino-acid derivatives. It also encompasses
increasing plasma circulation time and decreasing immunogenicity when
administering such modified antibodies and therapeutic agents to patients. The
invention thus pertains to the fields of chemical modification of bioactive
molecules and biomaterial science. Finally, the present invention relates to
15 biodegradable articles comprising at least a polymer sequence derived from the
said novel functional poly- α -amino-acid derivatives.

Background of the invention

In the past decades there has been a great interest in the use of end
group functionalized polyethylene glycol for the modification of peptides,
20 proteins, enzymes and non-peptide drugs. For instance, A. Abuchowski et al. in
J. Biol. Chem., 252, 3578-3581 (1977) and in *Cancer Biochem. Biophys.*, 7,
175-186 (1984) described modifying a protein by means of polyethylene glycol
grafted onto amino side groups along the said protein. It was shown by S.
Zalipsky, *Bioconjugate Chem.*, 6, 150-165 (1995) and by C. Delgado et al.,
25 *Critical Reviews in Therapeutic Drug Carrier Systems*, 9, (3,4), 249-304 (1992)
that polyethylene glycol grafted proteins exhibit a longer plasma half-life *in vivo*,
are less immunogenic and more thermostable.

Zalipsky (cited above), Delgado (cited above), T. M. Allen et al. in
Biochimica et Biophysica Acta, 1237, 99-108 (1995), J. M. Harris, Ed.
30 *Poly(Ethylene Glycol) Chemistry: Biotechnical and Biomedical Applications*, ed.,
Plenum Press, New York, 1992, and G. Hooftman et al. in *J. Bioact. Biocomp.
Polymers*, 11, 135-159 (1996) have reviewed a variety of methods for

introducing reactive groups at the chain end of polyethylene glycol which can react in a selective manner with protein functional side groups such as amino, thiol, guanidyl and the like.

Recently, polyethylene glycol has been used for the modification of synthetic vectors for gene delivery in order to prevent complexes with DNA from interactions with plasma proteins and erythrocytes and from enzymatic degradation in extra- and intracellular compartments (see for instance M.Ogris et al., *Gene Therapy* (1999) 6:595-605).

In biomaterial science, grafting of a polymer material surface with polyethylene glycol chains (hereinafter referred to as "PEG-ylation") has been extensively described as a method for improving surface biocompatibility. Surface PEG-ylation can be achieved by chemical grafting of polyethylene glycol onto a pre-formed surface as well as by applying a polymer having polyethylene glycol as a building part of its backbone or alternatively as a grafted side group. Such polymers can be used as a core material or be applied as a surface coating.

Polyethylene glycol is a rather stable polymer which is a repellent of protein adhesion and which is not subject to enzymatic or hydrolytic degradation under physiological conditions. However, biomedical applications are at every time looking for improved biocompatible polymeric materials. In particular, there is concern that polyethylene glycol, being not biodegradable, has difficulties to escape from cells and could be stored in cells, according to J. Lloyd, *Biochem.J.*, 261, 451-456 (1989). Therefore there is a need in the art for substituting polyethylene glycol, in such biomedical applications, by a polymer having similar properties but which is biodegradable. In another area, there is a need for the permanent grafting of polymer chains onto a polymer material surface. The above mentioned problems will be solved by the polymer and copolymer derivatives as described in this invention, containing functionalities that can be used to attach bioactive substances, e.g. short peptide molecules such as the tripeptide RGD (arginine-glycine-aspartic acid) and the like, or saccharides and oligosaccharides such as mannose and galactose. In yet another area, an object of the present invention is to provide improved synthetic

In a first embodiment, the present invention relates to novel poly- α -

amino-acid derivatives having a functional (i.e. reactive) group at one or both ends of the polymer backbone and/or only a single functional group as a side group on the polymer backbone, the said functional end group and/or side group being other than alcohol. Specifically, this embodiment relates to linear


5 poly- α -amino-acid derivatives having at least glutamic or aspartic or serinic repeating units and additionally having a functional (i.e. reactive) group at one or both ends of the polymer backbone and/or only a single functional (i.e. reactive) group as a side group on the said polymer backbone, the said functional end group and/or side group being other than alcohol. The reason for

10 providing a single functional group when pending as a side-group on the polymer backbone is the ability to obtain a very precise coupling of the poly- α -amino-acid derivative of the invention with specific proteins. The said functional (i.e. reactive) end group and/or side group may be any reactive group, other than alcohol, that may be attached to either end of and/or be pending on the

15 backbone of the said poly- α -amino-acid derivative containing at least glutamic or aspartic or serinic repeating units. In particular, it may be selected from the following functional groups: amine, carboxyl, ester, carbonate, thiol, thiol precursor (such as a disulfide), thioisocyanate, thiocarbonate, urea, thiourea, aldehyde, acetal, N-carboxyanhydride, oxycarbonyl (including carbonate ester,

20 2-oxycarbonyl pyridine, 2-oxycarbonyloxypyridine, succinimido carbonate, N-oxycarbonyl imidazole and the like) , maleimide or any vinyl group suitable for radical, anionic or cationic polymerization such as styryl, acrylate, methacrylate, acrylamide, methacrylamide, vinyl ether, propenyl ether and the like. The terms

25 "glutamic", "aspartic" and "serinic" as used herein, unless otherwise stated, are intended to mean the α -amino-acid sequence derived from glutamic acid or aspartic acid or serine respectively or, when available, from any ester or amide of such acids. More specifically, this embodiment relates to linear polymers having a number of repeating units of the formula:



30 wherein:

- R is defined as $-(\text{CH}_2)_n - \text{CO} - \text{OR}_1$ or $-(\text{CH}_2)_n - \text{CO} - \text{NHR}_2$ or CH_2OH ,
- n is 1 or 2,

- R_1 is selected from hydrogen, C_{1-20} alkyl, polyhalo C_{1-6} alkyl, aryl C_{1-6} alkyl and heteroaryl C_{1-6} alkyl, and
- R_2 is C_{1-6} alkyl substituted with at least one alcohol group, and further having a functional (i.e. reactive) group, such as above mentioned, at one or both ends of the polymer backbone and/or a single side group on the polymer backbone.

As will be detailed hereinafter, the novel poly- α -amino-acid derivatives of this invention are not limited to homopolymers comprising the said glutamic or aspartic or serinic repeating units, but they also include copolymers additionally comprising repeating units of one or more co-monomer(s) (hereinafter referred as A in the following formulae) copolymerizable with the α -amino-acid sequence derived from glutamic acid or aspartic acid or serine (such as hereinabove defined, i.e. including esters and amides thereof, when available). Non-limiting examples of such co-monomer repeating units include for instance any of the 17 naturally occurring α -amino-acids other than glutamic acid, aspartic acid and serine (in such case giving rise to either random or block copolymers) as well as polymer blocks or sequences derived from ethylene oxide or propylene oxide or mixtures thereof or from polyhydroxyalkanoates. Examples of the latter polymer sequences comprise for instance polymers and copolymers (whether random, block, segmented or grafted) of lactones such as ϵ -caprolactone, glycolide, L-lactide, D-lactide, meso-lactide, 1,4-dioxan-2-one, trimethylene carbonate (1,3-dioxan-2-one), γ -butyrolactone, δ -valerolactone, 1,5-dioxepan-2-one, 1,4-dioxepan-2-one, 3-methyl-1,4-dioxan-2,5-dione, 3,3 diethyl-1,4-dioxan-2,5-one, ϵ -decalactone, pivalolactone and 4,4-dimethyl-1,3-dioxan-2-one and the like. Several embodiments of such copolymers have been described by, among others, U.S.Patent No. 5,951,997, U.S.Patent No. 5,854,383 and U.S.Patent No. 5,703,200 and shall therefore be considered as being within the scope of the present invention.




In the above definitions of groups included namely in formula (I) of the repeating units, and in other parts of the present specification, unless otherwise stated, the terms used shall have the following meanings:

- halo is generic to fluoro, chloro, bromo and iodo;

- C₁₋₆ alkyl defines straight and branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as, for example, methyl, ethyl, propyl, n-butyl, 1-methylethyl, 2-methylpropyl, dimethylethyl, 2-methylbutyl, n-pentyl, dimethylpropyl, n-hexyl, 2-methylpentyl, 3-methylpentyl and the like;
- 5 - C₁₋₂₀ alkyl is meant to include C₁₋₆ alkyl (such as above defined) and the higher homologues thereof having 7 to 20 carbon atoms, such as for instance n-heptyl, 2-ethylhexyl, n-octyl, n-decyl, n-dodecyl, n-hexadecyl, n-octadecyl and the like;
- polyhaloC₁₋₆alkyl is defined as polyhalosubstituted C₁₋₆ alkyl, in particular
10 C₁₋₆ alkyl substituted with up to 8 halogen atoms such as difluoromethyl, trichloroethyl, trifluoromethyl, octafluoropentyl and the like;
- aryl is defined as a mono- or polyaromatic group, such as phenyl, optionally substituted with one to three substituents each independently selected from C₁₋₆ alkyl, nitro, cyano, halo and the like;
- 15 - heteroaryl is defined as mono- and polyheteroaromatic groups, i.e. containing delocalized π electrons, such as those including one or more heteroatoms, namely 1-hetero-2,4-cyclopentadienyl, azabenzenyl and fused-ring derivatives thereof, in particular pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl, triazinyl, tetrazinyl, benzothienyl, isobenzothienyl, benzofuranyl, isobenzofuranyl, benzothiazolyl, benzoxazolyl, indolyl, isoindolyl, purinyl, pyrazolopyrimidinyl, benzimidazolyl, quinolyl, isoquinolyl, cinnolyl, phtalazinyl, quinazolinyl, quinoxalinyl, thiazolopyridinyl, oxazolopyridinyl and imidazothiazolyl,
20 including all possible isomeric forms thereof, wherein each of said heteroaromatic groups may optionally be substituted with one or, where possible, two or three substituents each independently selected from C₁₋₄ alkyl (as, for instance, in N-alkyl-2,5- dialkylpyrrolyl, 2,5-dialkylfuranyl and 2,5-dialkylthienyl), C₁₋₄ alkyloxy, C₁₋₄ alkylcarbonyl, hydroxy, nitro, halo and
30 cyano;
- C₃₋₇ cycloalkyl is generic to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl;

When the α -amino-acid sequence of the poly- α -amino-acid derivative of this invention is a L-amino-acid sequence, the resulting polymer will be subject for enzymatic degradation and may conveniently be used for any purpose in biomaterial technology where polyethyleneglycol was previously used, including the chemical modification of biomolecules. On the other hand, when the α -amino-acid sequence of the poly- α -amino-acid derivative of this invention is a D-amino-acid sequence, the resulting polymer will be stable towards peptide degrading enzymes and may conveniently be used for the permanent surface modification of biomaterials.

As a general rule, the novel multifunctional (i.e. having at least two reactive groups, such as above defined, at the ends and/or on the side of the backbone) poly- α -amino-acid derivatives of the present invention may be described by any of the following formulae:



wherein:

- R is as defined in formula (I),
- x or, where applicable, x + x' range from 2 to about 2,000, preferably from 4 to about 500,
- each of V and W independently represent a functional (i.e. reactive) group, able to be attached to an end or on the side of the polymer backbone containing the repeating units of formula (I),
- A is at least a co-monomer co-polymerizable with the α -amino-acid sequence containing glutamic or aspartic or serinic repeating units,
- y ranges from 0 to about 500, preferably from 0 to about 100,
- T is a spacing unit selected from lysine and ornithine, and
- V' is a non-reactive end group.

In the above definition, "non-reactive end group" should be understood as meaning a chemical group which cannot be used for coupling with proteins. Non-limiting examples of such non-reactive end groups include C₁₋₂₀ alkyl, oxyC₁₋₂₀alkyl, aryl, arylC₁₋₂₀ alkyl, amide, heteroaryl and heteroarylC₁₋₂₀ alkyl.

5 For instance as previously mentioned, A may be represented by the formula
- CO - CHR' - NH - (III)

wherein R' is the side-chain group of an α -amino-acid other than glutamic acid or aspartic acid or serine. For example R' may be the side-chain group of any of the other 17 well known naturally occurring α -amino-acids, i.e. lysine, arginine,
10 histidine, glycine, asparagine, glutamine, cysteine, threonine, tyrosine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine and tryptophan.




In another mode of implementation of the invention, A may be represented by the formula - CH₂ - CHR'' - X' - (IV)
wherein:

15 - R'' is selected from hydrogen and methyl, and
- X' is selected from a single bond and oxygen,
i.e. [A]_y may be polyethylene glycol, polypropylene glycol and any copolymer of ethylene oxide and propylene oxide.

In still another mode of implementation of the invention, A may be at
20 least a repeating unit derived from a hydroxyalkanoate such as D or L lactic acid, glycolic acid, ϵ -caprolactone and the like. For instance, coupling of an amino-terminated poly- α -amino-acid derivative of this invention with a polyhydroxyalkanoate (based on one or more of the above-cited repeating units) having one or two hydroxyl end groups, e.g. in the presence of
25 carbonyldiimidazole, leads to amphiphilic di-block or tri-block copolymers which, if properly designed by those skilled in the art, are able to form micelles in an aqueous medium and can thus be suitably used as a drug delivery system, namely in order to store hydrophobic drugs in the resulting micelles.

Similarly, the novel monofunctional (i.e. having a single reactive group at
30 one end or on the side of the polymer backbone) poly- α -amino-acid derivatives of the present invention may be described by any of the following formulae:






5

wherein:

- R, x, x', A, y, T, V, V' and W are as defined in formulae (IIa) to (IIe), and
- W' is a non-reactive end group such as above defined in respect of V'.

A first preferred class of novel poly- α -amino-acid derivatives according to the invention is a class of derivatives with at least one protective end group, being represented by the following formulae:

10



15

wherein:


- R is $-(CH_2)_n-CO-NHR_2$,
- R₂ and n are as defined in formula (I),
- x is as defined in formulae (IIa) to (IIe),
- X₁ is $-R_4-Z_1-A_1$,
- each of R₃ and R₄ is independently selected from $(CH_2)_m$, arylene, C₁₋₆ alkylarylene and arylC₁₋₆ alkylene,
- m is from 2 to 20,
- Y₁ is $-Z_2-A_2$, X₂ is $-R_4-Z_3-A_3$ or $-O-R_4-Z_3-A_3$,
- Y₂ is $-Z_4-A_4$,
- each of Z₁, Z₂, Z₃ and Z₄ is independently selected from NH, O, S, C(O)O, C(S)O, CO, CS, $-OCH-O-$ and $C=N-R_5$,
- each of A₁, A₂, A₃ and A₄ is a protective group suitable for Z₁, Z₂, Z₃ and Z₄ respectively, and
- R₅ is selected from hydrogen, C₁₋₆ alkyl, aryl and C₁₋₆ alkylaryl, heteroaryl and C₁₋₆ alkylheteroaryl.

30

Protective groups A_1 , A_2 , A_3 and A_4 suitable for protecting Z_1 , Z_2 , Z_3 and Z_4 , i.e. NH, O, S, CO, CS and $C = N - R_5$ are well known to those skilled in the art of organic and peptide chemistry. An illustrative but non-limiting example of a group suitable for protecting the amino group NH is e.g. $-C(O)-O-CH_2-C_6H_5$.

5 Illustrative but non-limiting examples of groups suitable for protecting the sulfur atom include triphenylmethyl, 2-thiopyridyl and acyloxymethyl. Illustrative but non-limiting examples of a group suitable for protecting groups like CO, CS and $C = N - R_5$ or the oxygen atom are e.g. tetrahydropyranyl, tert-butyl and the like.



Another preferred class of novel poly- α -amino-acid derivatives according to the invention, which may serve namely as intermediate compounds for preparing the derivatives of formula (VII), is represented by the following formula:



- X_1 is as defined in formula (VII),
- 15 - x is as defined in any of formulae (IIa) to (IIe),
- R is defined as $-(CH_2)_n-CO-OR_1$, and
- R_1 and n are as defined in formula (I).

Another preferred class of novel poly- α -amino-acid derivatives according to the invention, which may serve namely as intermediate compounds, is represented by formula (VIII) wherein R is defined as being $-(CH_2)_n-CO-OR_1$ instead of being $-(CH_2)_n-CO-NHR_2$.

Another preferred class of derivatives has reactive end groups that can be covalently coupled with a functional group selected from amine, alcohol, thiol, carboxylic acid, disulfide and maleimide, or that contain polymerizable end groups. They may be represented by the formulae, respectively (X) and (XI):



30 In a second embodiment, the present invention relates to processes for obtaining the novel monofunctional and heterobifunctional poly- α -amino-acid derivatives described hereinabove (the term "heterobifunctional" here should be









understood as referring to derivatives having the above formulae and wherein the functional groups V and W are different from each other). As a general procedure, such processes include a step comprising polymerizing a monomer or mixture of monomers comprising at least the N-carboxy-anhydride of an amino-acid selected from glutamic acid, aspartic acid, serine and oxygen-protected serine in the presence of an effective amount of a multifunctional initiator containing at least one primary amino group and further containing at least another functional group selected from maleimide, thioisocyanate, thiocarbonate, urea, thiourea, aldehyde, acetal, oxycarbonyl, vinyl (such as acrylate, methacrylate, acrylamide, methacrylamide and the like), ester, carbonate, thiol precursor, protected amine and protected carboxylic acid and/or in the presence of an effective amount of a bi-functional terminating reagent. The terms "oxygen-protected serine", "protected amine" and "protected carboxylic acid" as used herein are well understood from those skilled in the art of peptide chemistry. Illustrative and non-limiting examples of most common multifunctional initiators include amino-acid esters, α -amino- ω -diC₁₋₆alkylacetals, α,α' -diamino C₁₋₆alkyldisulfides and α -amino- ω -maleimido alkanoic acid amides. Initiation using a multifunctional initiator and termination by adding a monofunctional terminating reagent as well as initiation using a monofunctional initiator and termination by adding a bifunctional terminating reagent leads to derivatives with one single functional (i.e. reactive) group at one end of the linear polymer backbone. A combination of multifunctional initiation and bifunctional termination reactions provides a polymer with functional (i.e. reactive) groups at both ends of the linear polymer backbone.

Initiation by a diamine having a protected carboxyl group, such as the tertbutylester or the ω -amino alkylacyl derivatives of lysine or ornithine, leads to a poly- α -amino-acid derivative having a single pendant protected carboxyl side group. If the terminating reagent is monofunctional, then the chain ends will be non reactive. If the terminating reagent is heterobifunctional, then the chain ends will be reactive. If no terminating reagent is used, then the polymer backbone will have amino end groups.

If during the polymerization of the N-carboxy anhydride of glutamic acid,







aspartic acid, serine or oxygen-protected serine, termination would occur by formation of a pyrrolidone end group, then this process will only be applicable for preparing derivatives having one single functional group. However, in such event, heterofunctional derivatives can still be prepared by the alternative so-called "activated monomer process" described below and schematically represented in figure 1.

Non limiting examples of multifunctional initiators which can be used in the process of the invention are:



The initiator having the formula (XII), which may be obtained by reacting a commercially available compound represented by the formula (XIV) hereunder with a diamine $H_2N - (CH_2)_n - NH_2$, is believed to be a novel organic reagent, as well as the initiator having the formula (XIII) which may be obtained by reacting monotriethylamine with N-succinimidyl 3-(2-pyridyldithio) propionate.

Non limiting examples of terminating reagents which can be used in the process of the present invention are:




Illustrative but non-limiting examples of the principal monomers suitable for performing the above-mentioned polymerization step of the process of the

polymerization step. An effective amount of the activating agent or reaction promoter to be used during the said aminolysis step usually ranges from about 0.5 to 5 equivalents with respect to the monomeric units in the polymer formed in the previous polymerization step. The aminolysis step of the process of this invention preferably takes place in the presence of a solvent for the polymer derived from the N-carboxy-anhydride of glutamic acid, aspartic acid, serine or oxygen-protected serine. Examples of suitable solvents for this aminolysis step are namely aprotic solvents including amides such as dimethylformamide, N-methylpyrrolidone or dimethylacetamide, dimethylsulfoxide, esters such as ethyl acetate and the like.

For instance, the synthesis of poly[N⁵-(2-hydroxy-ethyl)-L-glutamine] (PHEG) may be performed by first polymerizing the N-carboxy-anhydride of γ -benzyl-L-glutamate or γ -trichloroethyl-L-glutamate, followed by aminolysis of the resulting poly- γ -benzyl-L-glutamate or poly- γ -trichloroethyl-L-glutamate using a large excess of 2-aminoethanol in presence of 2-hydroxypyridine.

This first route for obtaining the novel functional poly- α -amino-acid derivatives of the invention without termination due to the formation of a pyrrolidone end group may be represented by the sequence of chemical reactions shown in figure 1 and now explained in further details:


a) polymerization step:



b) end-group functionalization step

This step proceeds through reaction of the compound of formula (IX) with a

reactive ester or anhydride having the formula $Y_1 - R_3 - \text{COOR}_6$, wherein R_6 is a reactive ester or anhydride.



wherein R is $-(\text{CH}_2)_n-\text{CO}-\text{NHR}_2$

Mono- and bifunctional poly α -amino-acid derivatives according to the invention may also alternatively be prepared by the so-called "activated monomer mechanism" of polymerization of N-carboxy anhydrides as schematically represented on figure 1:

a) preparation of a suitable N-carboxy anhydride mixture from the α -aminoacid.

In this first step, part of the relevant α -amino-acid (for instance glutamic acid, aspartic acid or serine) is N-acylated, for instance by means of an haloformate or carbonyl halide having the formula X_2COX wherein X is a halogen atom such as chlorine and X_2 is as defined in formula (VIII), then both the N-acylated α -amino-acid and the remaining part of the same α -amino-acid are separately treated, for instance by means of phosgene or diphosgene, in order to form both N-carboxy anhydrides shown below. Non limiting examples of haloformates which can suitably be used for this first step are:

the second step is reacted with a reagent having the formula $H_2N - R_3 - Y_2$, wherein R_3 and Y_2 are as defined in formula (VIII). If the said terminating reagent $H_2N - R_3 - Y_2$ is a diamine containing a protected carboxyl group, then the said termination reaction will lead to a poly- α -amino-acid derivative having one single protected carboxyl side group.

Non-limiting examples of functionalized amines suitable for use in this step of the second process of the invention may be taken for instance from the list of multifunctional initiators provided hereinbefore in relation with the first process of the invention.

d) aminolysis step

As shown hereinbelow, this step proceeds essentially as in the first route of obtention previously described.

As an example, a heterobifunctional derivative of the invention can be prepared via this second procedure by polymerization of γ -benzyl-L-glutamate or the N-carboxyanhydride of γ -trichloroethyl-L-glutamate (TCEG-NCA) (in excess) with N-acylated TCEG-NCA and using tributylamine as an initiator, followed by termination with a compound containing a functional amino end group (or a diamine having a protected carboxylic group) and another functional end group, and subsequent aminolysis of the trichloroethylester side groups with ethanolamine.

In a third embodiment, the present invention relates to biodegradable articles containing a copolymer comprising at least a moiety derived from a poly- α -amino-acid derivative such as above described, particularly one having any of the formulae (IIa), (IIb), (IIc), (IId), (IIe), (Va), (Vb), (Vc), (Vd), (VI), (VII) and (VIII), provided that the functional group at one or both ends thereof - i.e. V and/or W in formulae (IIa), (IIb), (IIc), (IId), (IIe), (Va), (Vb), (Vc), (Vd) and (VI), $R_3 - Y_2$ and/or $R_3 - Y_1$ in formulae (VII) and (VIII) - is an unsaturated group, and at least a moiety derived from an unsaturated comonomer copolymerizable therewith. The said unsaturated comonomer copolymerizable with the unsaturated poly- α -amino-acid derivative of the present invention may be for instance an α -olefin, an α,β -unsaturated monocarboxylic acid, ester, nitrile or

amide (such as acrylic, methacrylic and the like), an unsaturated dicarboxylic acid anhydride (such as maleic anhydride) or any other vinyl terminated monomer (such as styrene, α -methylstyrene, vinyl ether, propenyl ether and the like) or any combination thereof. The respective proportions of the said
5 unsaturated comonomer and of the said unsaturated poly- α -aminoacid derivative may easily be selected and adapted by those skilled in the art, depending on the reactivity ratio of the said comonomers and on the biodegradability level and kinetics to be achieved in the final biodegradable article, which may in addition comprise usual biodegradability additives.

10 In a fourth embodiment, the present invention relates to the use of a novel functional poly- α -amino acid derivative such as above described, particularly one having any of the formulae (IIa), (IIb), (IIc), (IId), (Ile), (Va), (Vb), (Vc), (Vd), (VI), (VII), (VIII) and (IX), for the modification of a biologically-active ingredient. This invention therefore also relates to any product resulting from
15 such modification, including the product of coupling it with or grafting it onto the said biomolecule. As already indicated hereinabove, derivatives containing a L-amino-acid sequence, being enzymatically degradable, are most useful for this purpose. The biologically-active ingredient to be modified according to this invention, preferably to be used in a biologically effective amount, may be such
20 as a therapeutic, diagnostic or prophylactic agent. The therapeutic agent or drug can be selected for its antimicrobial properties, capability for promoting repair or reconstruction of specific tissues or for specific indications. These include for instance antimicrobial agents such as broad spectrum antibiotics for combating clinical and sub-clinical infections, for example gentamycin, vancomycine and the like. Other therapeutic agents or drugs which can be
25 considered for modification by means of the poly- α -aminoacid derivative of this invention are naturally occurring or synthetic organic or inorganic compounds well known in the art, including proteins and peptides (produced either by isolation from natural sources or recombinantly), hormones, carbohydrates, antineoplastic agents, antiangiogenic agents, vasoactive agents, anticoagulants, immunomodulators, cytotoxic agents, antiviral agents,
30 antibodies, neurotransmitters, oligonucleotides, lipids, plasmids, DNA and the

like. Therapeutically active proteins which can additionally be modified according to this invention include, without any specific limitation, fibroblast growth factors, epidermal growth factors, platelet-derived growth factors, macrophage-derived growth factors such as granulocyte macrophage colony stimulating factors, ciliary neurotrophic factors, cystic fibrosis regulator genes, tissue plasminogen activator, B cell stimulating factors, cartilage induction factor, differentiating factors, growth hormone releasing factors, human growth hormone, hepatocyte growth factors, immunoglobulins, insulin-like growth factors, interleukins, cytokines, interferons, tumor necrosis factors, nerve growth factors, endothelial growth factors, non-steroidal anti-inflammatory drugs, osteogenic factor extract, T cell growth factors, tumor growth inhibitors, enzymes (e.g. superoxide dismutase, asparaginase, ribonuclease, adenine deaminase, xanthine oxidase and the like), as well as fragments thereof. Other biomolecules which can also be modified in this way include human serum albumin, lysine, cysteine and the like.

Diagnostic agents which can be regarded as biologically-active ingredients to be modified according to this invention (and to be used preferably in an effective amount for performing the relevant diagnostic) include, without any specific limitation, conventional imaging agents (for instance as used in tomography, fluoroscopy, magnetic resonance imaging and the like) such as transition metal chelates.

The novel functional poly- α -aminoacid derivatives of this invention are also useful for the modification of antibodies, and fragments thereof, having a thiol group and/or an amino group. More specifically, the present invention relates to antibodies modified by means of the said functional poly- α -aminoacid derivatives and having a second functionality for hooking and/or being able to attach another targeting group such as an antibody or a fragment thereof, an oligopeptide that is recognized by cell membrane integrines, such as the tripeptide RGD (arginine-glycine-aspartic acid), the tetrapeptide RGDS (meaning RGD-serine) or the like (as is well known to those skilled in the art, RGD is found in the integrin-binding domains of a number of ligands, and sequences flanking this tripeptide are presumed to determine the exact binding

specificity), peptides (such as mellitin) which stimulate cell membrane penetration, transferrin, saccharides and oligosaccharides such as galactose, mannose and the like.

As already indicated hereinabove, derivatives containing a D-aminoacid
 5 sequence are useful for the surface modification of biomaterials. Such modified surfaces may be obtained either by grafting poly- α -amino acid derivatives such as PHEG on the surface or by coating the surface with a PHEG-containing copolymer. As an example, poly-[N-(2-hydroxyethyl)-L-glutamine] having an
 10 unsaturated end group (such as styryl, acrylate, acrylamide, methacrylate, methacrylamide and the like) can be adsorbed from a solution containing Eosin Y and triethanolamine onto a material surface. Subsequent light irradiation results in polymerization of the unsaturated end groups. Via the same procedure, comonomers and crosslinking agents such as a bismethacrylate can also be co-adsorbed and copolymerized. Another method of using poly-[N-(2-
 15 hydroxyethyl)-L-glutamine] having an unsaturated end group consist of copolymerizing it with a comonomer and to apply the resulting copolymer from solution onto a substrate. Yet another method consist of generating reactive groups (such as carboxylic acid or anhydride) onto a material surface and then to make them react with a suitable PHEG-end group (e.g. an amino end group).

20 The novel functional poly- α -amino acid derivatives of this invention are also useful for the building-up and/or the modification of a synthetic vector component, for instance for gene delivery, such as polyethyleneimine (either branched or linear), poly-L-lysine, a star-shaped dendrimer (e.g. of the polypropyleneimine type or the polyamido-amine type) or chitosan. Thus the
 25 present invention contributes to solve the problem of efficient delivery to target cells *in vivo*. At present viruses provide the most popular vectors for *in vivo* delivery, particularly with improved DNA packaging techniques. However, their inherent immunogenicity, possibility of fixing complement, poor target selectivity and difficulty of scale-up production, together with concerns over potential
 30 toxicity, seem likely to prevent their widespread acceptance. There is therefore a need for alternative safe and efficient DNA or gene delivery systems preferably based on fully synthetic carrier vehicles. A synthetic carrier vehicle or


vector suitable for efficient targeted delivery of DNA or other nucleic acid material *in vivo* must fulfil various biological requirements. Ideally it would be stable in the blood circulation, non-immunogenic and resistant to enzymatic degradation, capable of efficient target-discrimination, and able to penetrate the target cell membrane selectively to gain access to the nucleus, release the nucleic acid and enable efficient transcription within the target cell. For successful and versatile *in vivo* application it is very important that nucleic acid delivery vehicles should be small enough to gain access to target cells.

Therefore another embodiment of the present invention is a synthetic polymer for a polymer-based carrier vehicle or vector for delivery of DNA or other nucleic acid material to target cells in a biological system, comprising a linear poly- α -amino-acid derivative such as above described. In particular the said polymer may be one having any of formulae (IIa), (IIb), (IIc), (IId), (IIe), (Va), (Vb), (Vc), (Vd), (VI), (VII), (VIII) and (IX). The nucleic acid material may include for instance genomic DNA, DNA fragments of any length, plasmid DNA, cDNA, RNA, oligonucleotides, DNA expression vectors, RNA, ribozymes and the like. Antisense nucleic acid may also be used for certain therapies. In the DNA carrier vehicles provided by this invention, the DNA expression vector usually is a plasmid-based expression vector incorporating an appropriate promoter sequence.

Yet another embodiment of the present invention is a method of treatment of a patient (i.e. a mammal, preferably a human) in need of such treatment, comprising administration to said patient of a biologically-active ingredient (such as above disclosed) modified by or a nucleic acid material carried by a polymer system comprising a linear poly- α -amino-acid derivative such as disclosed above in details. For instance, the invention provides a method of delivering gene DNA material to a patient in carrying out somatic gene therapy treatment, said method comprising packaging the selected DNA as a expression vector in a carrier vehicle constructed as herein described, and administering the polyelectrolyte complex material forming the DNA carrier vehicle to said patient.

EXAMPLE 1 – polymerisation of N-carboxyanhydride of γ -trichloroethyl-L-glutamate.


2 g of N-Carboxyanhydride of γ -trichloroethyl-L-glutamate (TCEG-NCA, obtained for instance from glutamic acid, trichloroethanol and phosgene) is dissolved in 20 ml dry 1,2-dichloroethane and the resulting solution is cooled down to 10°C. 1-Triphenylmethylaminoethylamine (0,099 g, i.e. 5 mole% with respect to TCEG-NCA) is dissolved in 2 ml 1,2-dichloroethane and added to the solution of TCEG-NCA. Polymerisation of TCEG-NCA is then effected by maintaining the temperature at 10°C. After two hours, polymerisation is determined to be complete by infrared spectroscopy, then a three-fold molar excess of acetic anhydride and equimolar quantity of triethylamine are added and the reaction mixture is stirred for another two hours at room temperature. The solution is precipitated in pentane and the polymer produced is isolated by filtration and dried under vacuum. Its molecular weight is determined by ¹H NMR (DMF-d₇) and gel permeation chromatography (polystyrene standard, tetrahydrofuran as eluent) to be M_n = 6,000. ¹H NMR (DMF-d₇) analysis confirms the following structure of the polymer:



EXAMPLE 2 - aminolysis of the trichloroethylester of poly-L-glutamic acid.

1 g (3,8 mmole) of the polymer obtained in example 1 is dissolved in 10 ml dry N,N-dimethylformamide. This solution is cooled down to 10°C and 0,69 ml (11,5 mmole) ethanolamine and 0,36 g (3,8 mmole) 2-hydroxypyridine are then added. The reaction is followed by infrared spectroscopy and, after two hours, determined to be complete (100% conversion). The resulting aminolysed


polymer is isolated by precipitation in ether, filtrated, dried under vacuum and then purified by gel filtration on Sephadex G-25 (water as eluent) and isolated by lyophilization. The purified polymer is characterised by ^1H NMR (D_2O) and gel permeation chromatography (dextran standards, water as eluent) as having
 5 a molecular weight M_n of 4,000. ^1H NMR analysis confirms the following structure for this polymer:



EXAMPLE 3 - deprotection of poly-[N-(2-hydroxyethyl)-L-glutamine] (PHEG)

1 g of the polymer of example 2 is dissolved in 10 ml trifluoroacetic acid and stirred at room temperature for half an hour. Trifluoroacetic acid is then removed by evaporation under vacuum. The resulting polymer is dissolved in
 20 water and centrifugated, then the supernatant is purified by gel filtration on Sephadex G-25 (water as eluent) and isolated by lyophilization.


^1H NMR ($\text{D}_2\text{O}/\text{DCI}$) analysis confirms the following structure of the polymer:



EXAMPLE 4 – functionalization of poly-[N-(2-hydroxyethyl)-L-glutamine] by means of disulfide groups.

1 g of the polymer of example 3 is dissolved in 0,1 M phosphate buffer,

pH 7,5 (100 ml). 0.6 g N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP) is dissolved in 30 ml ethanol and added to the polymer solution. After two hours reaction at room temperature, the mixture is separated on Sephadex G-25 (water as eluent) and the resulting functional polymer (PHEG-SPDP) is isolated by lyophilization. ¹H NMR (D₂O) analysis confirms the following structure of the polymer:




The concentration of pyridyldithio groups is determined also in the presence of 0.1 M dithiothreitol (hereinafter referred to as DTT), using $\epsilon = 8080 \text{ M}^{-1}\text{cm}^{-1}$ at 343 nm for released pyridine-2-thione.

EXAMPLE 5 – functionalization of poly-[N-(2-hydroxyethyl)-L-glutamine] by means of thiol end group.

The functional polymer of example 4 (PHEG-SPDP) is dissolved in 0,1 M acetate buffer, pH 4,5, containing 0,1 M NaCl (10 mg/ml), and DTT is added to provide a concentration of 10 mM. After 30 minutes at room temperature, the DTT-treated mixture is desalted into 0,1 M sodium phosphate buffer (pH 7.2) containing 1mM ethylenediaminetetraacetic acid (EDTA). The number of thiol groups generated is determined by means of 5,5'-dithiobis(2-nitrobenzoic acid).

EXAMPLE 6 – functionalization of poly-[N-(2-hydroxyethyl)-L-glutamine] by means of maleimide end group.


1 g of the polymer of example 3 is dissolved in 0,1 M phosphate buffer, pH 7.0 (200 ml). Maleimidobenzoyl-N-hydroxysuccinimide ester (0.2 g) is dissolved in 10 ml N,N-dimethylformamide and added to the polymer solution. After stirring at room temperature for 1 hour, the mixture is separated on Sephadex G-25 (water as eluent) and the resulting functional polymer is isolated by



TCEG-NCA (2 g) is dissolved in 20 ml dry 1,2-dichloroethane and the solution is cooled down to 10°C. 2-Methoxyethylamine (0,023 g, i.e. 5 mole% with respect to TCEG-NCA) is dissolved in 2 ml 1,2-dichloroethane and added to the previous solution. After two hours, polymerisation is determined by infrared spectroscopy to be complete, then a three-fold molar excess of methacrylic anhydride and equimolar quantity of triethylamine are added and the reaction mixture is stirred for another two hours at room temperature. The solution is precipitated in pentane and the polymer is isolated by filtration and dried under vacuum. The molecular weight is determined by ¹H NMR (DMF-d₇) and gel permeation chromatography (polystyrene standard, tetrahydrofuran as eluent) to be 6,500. ¹H NMR (DMF-d₇) analysis confirms the following structure of the polymer:


TCEG-NCA (2 g) is dissolved in 20 ml dry 1,2-dichloroethane, then the solution is cooled down to 10°C. 2-Methoxyethylamine (0,023 g, 5 mole % with respect to TCEG-NCA) is dissolved in 1,2-dichloroethane (2 ml) and added to the previous solution. After two hours, polymerisation is determined by infrared spectroscopy to be complete, then a three-fold molar excess of succinic anhydride and equimolar quantity of triethylamine are added and the reaction mixture is stirred for 24 hours at room temperature. Then 1.2 g citric acid is dissolved in 50 ml water and added to the reaction mixture. The resulting polymer is extracted with 1,2-dichloroethane, the solution is dried over MgSO_4 .

and precipitated in pentane. The polymer is isolated by filtration and dried under vacuum. ¹H NMR (DMF-d₇) confirms the following structure of the polymer obtained:










EXAMPLE 13 - aminolysis of trichloroethyl ester of poly-L-glutamic acid

- 5 The aminolysis of the polymer of example 12 is carried out while using the procedure as described in example 2. ¹H NMR (D₂O) confirms the following structure of the polymer obtained:






15 EXAMPLE 14 – preparation of poly-[N-(3-hydroxypropyl)-L-glutamine] with functional end groups.

- 20 Polymerisation of TCEG-NCA is first initiated by means of suitable initiators or terminated by means of suitable terminating agents as described in examples 1, 6 and 7. Then aminolysis of such polymers is carried out as described in example 2, except that ethanolamine is replaced with 3-amino-1-propanol. After deprotection (as in example 3) or hydrolysis (as in example 9), functional polymers having the following structures were obtained:




EXAMPLE 15 - preparation of poly-[N-(2,3-dihydroxypropyl)-L-glutamine] with functional end groups.

20 Polymerisation of TCEG-NCA is first initiated by means of suitable initiators or terminated by means of suitable terminating agents as described in examples 1, 6 and 7. Then aminolysis of such polymers is carried out as described in example 2, except that ethanolamine is replaced with 3-amino-1,2-propanediol. After deprotection (as in example 3) or hydrolysis (as in example 9), functional polymers having the following structures were obtained:




EXAMPLE 16 - polymerisation of N-carboxyanhydride of γ -trichloroethyl-L-aspartate.

N-Carboxyanhydride of γ -trichloroethyl-L-aspartate (TCEA-NCA) (2 g) is dissolved in 20 ml dry 1,2-dichloroethane, then the solution is cooled down to 10°C. 1-Triphenylmethylaminoethylamine (0,099 g, i.e. 5 mole % with respect to TCEA-NCA) is dissolved in 1,2-dichloroethane (2 ml) and added to the previous solution. After two hours, polymerisation is determined by infrared spectroscopy to be complete, then a three-fold molar excess of acetic anhydride and equimolar quantity of triethylamine are added and the reaction mixture is stirred for another two hours at room temperature. The solution is then precipitated in pentane and the resulting polymer is isolated by filtration and dried under vacuum. The molecular weight is determined by 1H NMR (DMF- d_7) and gel permeation chromatography (polystyrene standard, tetrahydrofuran as eluent) to be $M_n = 5,000$. 1H NMR (DMF- d_7) analysis confirms the following structure of the polymer:



10 EXAMPLE 17 - aminolysis of trichloroethyl ester of poly-L-aspartic acid.


1 g (3,8 mmole) of the polymer of example 16 is dissolved in 10 ml dry N,N-dimethylformamide. This solution is cooled down to 10°C, then 0,69 ml (11,5 mmole) ethanolamine and 0,36 g (3,8 mmole) 2-hydroxypyridine are added. The reaction is followed by infrared spectroscopy and, after two hours, determined to be complete (100% conversion). The resulting aminolyzed polymer is isolated by precipitation in ether, filtrated and dried under vacuum and then purified by gel filtration on Sephadex G-25 (water as eluent) and isolated by lyophilization. The purified polymer is characterised by ^1H NMR (D_2O) and gel permeation chromatography (dextran standard, water as eluent) as having a molecular weight M_n of 3,500. ^1H NMR analysis confirms the following structure of the polymer:



EXAMPLE 18 - deprotection of poly-[N-(2-hydroxyethyl)-L-aspartate]

1 g of the polymer of example 17 is dissolved in 10 ml trifluoroacetic acid

and stirred at room temperature for half an hour. Trifluoroacetic acid is removed by evaporation under vacuum. The polymer is dissolved in water and centrifugated, then the supernatant is purified by gel filtration on Sephadex G-25 (water as eluent) and isolated by lyophilization. ^1H NMR ($\text{D}_2\text{O}/\text{DCI}$) analysis confirms the following structure of the polymer:



EXAMPLE 19 - coupling of an aldehyde-terminated PHEG with human serum albumin.

The aldehyde-terminated poly-[N-(2-hydroxyethyl)-L-glutamine] (PHEG) of example 9 in a 0,1 M sodium acetate buffer (10 mg/ml) at pH 4.0 is added to a solution of human serum albumin (hereinafter referred to as HAS) in the same buffer (10 mg/ml). After 16 hours at room temperature, the resulting product is purified by gel filtration chromatography on Sephadex G-50 equilibrated with phosphate buffer saline (hereinafter referred to as PBS). Fractions containing purified 1:1 PHEG-CH=N-HSA conjugates are pooled, concentrated by precipitation with ammonium sulfate, dissolved into PBS, and stored at 4°C. When coupling was carried out in the presence of a reducing agent, e.g. sodium cyanoborohydride, a more stable conjugate PHEG-CH₂NH-HSA was obtained.

EXAMPLE 20 - coupling of a disulfide-terminated PHEG with human serum albumin.

First, thiolation of HSA is effected according to the following procedure: to HSA (10mg/ml) in PBS is added a five-fold excess of SPDP dissolved in a minimal amount of dimethylformamide. After stirring at room temperature for 30 minutes, the solution is desalted into 0,1 M acetate buffer (pH 4.5) containing 0,1 M NaCl and dithiothreitol (DTT) is added to give a concentration of 10 mM. After 20 minutes at room temperature, the DTT-treated mixture is desalted into

0,1 M sodium phosphate buffer (pH 7,2) containing 1 mM ethylenediaminetetraacetic acid (EDTA). The number of thiol groups generated is determined by means of 5,5'-dithiobis(2-nitrobenzoic acid).

Then thiolated HSA is reacted with a disulfide-terminated PHEG as follows : the polymer of example 4 in 0,1 M sodium phosphate buffer (pH 7.2) containing 1mM EDTA (10 mg/ml) is mixed with thiolated HSA in the same buffer to provide a 4:1 HAS/PHEG molar ratio. After stirring at room temperature for 16 hours, the conjugate obtained is purified by gel filtration chromatography on Sephadex G-50 equilibrated with PBS. Fractions containing purified 1:1 HSA-SS-PHEG conjugates are pooled, concentrated by precipitation with ammonium sulfate, dissolved into PBS, and stored at 4°C. The same conjugate can also be prepared by reacting the functional PHEG of example 5 with HAS modified by SPDP at similar conditions.

EXAMPLE 21 - coupling of a maleimide-terminated PHEG with human serum albumin.

First, thiolation of HSA is carried out as described in example 20. Then thiolated HSA is reacted with a maleimide-terminated PHEG as follows: for the preparation of a conjugate with a thioether bond, the polymer of example 6 in 0,1 M sodium phosphate buffer (pH 7.2) containing 1mM EDTA (10 mg/ml) is mixed with thiolated HSA in the same buffer in order to provide a 4:1 HAS/PHEG molar ratio. After stirring at room temperature for 16 hours, the conjugate obtained is purified by gel filtration chromatography on Sephadex G-50 equilibrated with PBS. Fractions containing purified 1:1 HSA-S-PHEG conjugates are pooled, concentrated by precipitation with ammonium sulfate, dissolved into PBS, and stored at 4°C.

EXAMPLE 22 - biodegradation of poly[N-(2-hydroxyethyl)-L-glutamines]

10 mg of a poly[N-(2-hydroxyethyl)-L-glutamine] (PHEG) produced according to example 3, except that its molecular weight M_n is 102,000 is dissolved in 1,2 ml phosphate-citrate buffer (pH 5.5) containing 0,2% (weight/volume) Triton X-100. 200 μ l EDTA (10 ml in buffer), 200 μ l reduced glutathion (50 ml in buffer) and 400 μ l tritosomes (2,5 mg/ml in buffer) are added. These mixtures are incubated at 37 °C. Samples are taken at

PHEG with carboxylic end group from example 13 is dissolved in 0.1 M phosphate buffer (10mg/ml), pH 7.4. 1-Ethyl-3-(dimethylaminopropyl) carbodiimide hydrochloride (1 equivalent) is added. Superoxide dismutase (SOD) is dissolved in the same buffer (10 mg/ml) and added to the above solution. After 1 hour at room temperature the product is purified as in example 23 and lyophilized. The degree of substitution, determined by TNBS method, is 40 mole %.

EXAMPLE 25 - coupling of an aldehyde-terminated PHEG with polyethyleneimine

The aldehyde-terminated poly-[N-(2-hydroxyethyl)-L-glutamine] (PHEG) of example 9 in 0,1 M phosphate buffer (10mg/ml), pH 5.5, is added to a solution of polyethyleneimine (hereinafter referred to as PEI) in the same buffer (10 mg/ml). After 2 hours at room temperature the product is reduced by means of sodium cyanoborohydrate and a stable conjugate, PEI-g-PHEG, is obtained. The product is purified as in example 23 and lyophilized. The degree of substitution, determined by using ¹H NMR spectroscopy and TNBS method, is 20 mole %. Similar conjugates can be prepared by coupling the said aldehyde-terminated PHEG with poly-L-lysine or another cationic polymer containing primary amino groups in its side chains.

EXAMPLE 26 - coupling of a carboxylic-terminated PHEG with poly-L-lysine

PHEG with carboxylic end group from example 13 is dissolved in 0.1 M phosphate buffer (10mg/ml), pH 7.4. 1 equivalent of 1-ethyl-3-(dimethylaminopropyl) carbodiimide hydrochloride is added. Poly-L-lysine (hereinafter referred to as PPL) is dissolved in the same buffer (10 mg/ml) and added to the above solution. After 2 hours at room temperature the conjugate obtained, PLL-g-PHEG, is purified as in example 23 and lyophilized. The degree of substitution, determined by ¹H NMR spectroscopy and TNBS method, is 20 mole %.

EXAMPLE 27 - Synthesis of N-acylated N-carboxyanhydride of γ -trichloroethyl-L-glutamate

This synthesis procedure is presented in the scheme shown below and comprises the following steps:


a) synthesis of tertbutoxycarbonyl aminoethanol:

A solution of 2.1 ml ethanolamine (10 mmole) in a mixture of dioxane (20 ml), water (10 ml) and 1N NaOH (10 ml) is cooled in an ice-water bath. 2.4 g Di-tert-butyl dicarbonate (11 mmole) is added with stirring and the reaction proceeds for ½ hour. The solution is concentrated under vacuum, cooled in an ice-water bath, covered with a layer of ethyl acetate (30 ml) and acidified with a dilute solution of KHSO₄ to pH 2-3. The aqueous phase is extracted with ethyl


1 g N-acylated trichloroethyl monoester of L-glutamic acid (2 mmole) is dissolved in 30 ml tetrahydrofuran under stirring. 0.4 g diphosgene (2 mmole) is added in portions, the solution is stirred under reflux for 2 hours and flashed with nitrogen gas under stirring for another 2 hours. The resulting product is precipitated in pentane, filtered and dried under vacuum, yielding 75 % of N-acylated N-carboxyanhydride of γ -trichloroethyl-L-glutamate, the structure of which is confirmed by ^1H NMR (CDCl_3) analysis.

EXAMPLE 28 - polymerization of TCEG-NCA with N-acylated TCEG-NCA

2 g N-carboxyanhydride of γ -trichloroethyl-L-glutamate (TCEG-NCA) is dissolved in 20 ml dichloromethane. Solutions of the N-acylated TCEG-NCA (0.17 g, i.e. 5 mole % with respect to TCEG-NCA) in 5 ml dichloromethane and tributylamine (0.06 g, i.e. 5 mole % with respect to TCEG-NCA) in 2 ml dichloroethane are added to the solution of TCEG-NCA. After the end of the polymerization (about 3 hours), determined by infrared spectroscopy, a solution of 2-aminoethyl propionamide-3-maleimide (prepared from triphenylmethyl ethylamine and 6-maleimidocaproic acid and then deprotected with trifluoroacetic acid) (three-fold excess with respect to the initiator) in 5 ml dichloromethane and an equimolar amount of triethylamine are added and the reaction mixture is stirred for another 3 hours at room temperature. The solution is precipitated in pentane and the resulting polymer is isolated by filtration and dried under vacuum. Its molecular weight, determined by ^1H NMR (DMF-d_7), is 6,000. ^1H NMR (DMF-d_7) confirms the following structure of the polymer:


EXAMPLE 29 - aminolysis of a poly- γ -trichloroethyl-L-glutamate containing a maleimido end group and a tertbutoxycarbonyl N-acylated end group.

The aminolysis procedure is performed as in example 2, resulting in a polymer with a molecular weight, determined by ^1H NMR (D_2O), of 4,000. ^1H NMR (D_2O) confirms the following structure of the polymer:



EXAMPLE 30 - deprotection of a tertbutoxycarbonyl group in a polymer.


- 1 g of the polymer of example 29 is dissolved in 10 ml trifluoroacetic acid and stirred at room temperature for 0,5 hour. Trifluoroacetic acid is removed by evaporation under vacuum. The resulting polymer is dissolved in water and centrifugated. The supernatant product is purified by gel filtration on Sephadex G-25 (water as eluent) and isolated by lyophilization. ¹H NMR (D₂O) confirms the following structure of the polymer:



EXAMPLE 31 - synthesis of a heterobifunctional PHEG.


- 10 a) polymerization of N-carboxyanhydride of γ -trichloroethyl-L- glutamate
- 2 g N-Carboxyanhydride of γ -trichloroethyl-L- glutamate (TCEG-NCA) is dissolved in 20 ml dry 1,2-dichloroethane. The solution is cooled down to 10°C. 0,099 g 1-triphenylmethylaminoethylamine (5 mole % with respect to TCEG-NCA) is dissolved in 2 ml 1,2-dichloroethane and added to the solution of NCA.
- 15 After the end of the polymerisation, determined by infrared spectroscopy, a three-fold molar excess of N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP) is added and the reaction mixture is stirred for another 2 hours at room temperature. The solution is precipitated in pentane and the resulting polymer is

isolated by filtration and drying under vacuum. Its molecular weight, determined by ^1H NMR (DMF-d_7) and GPC (polystyrene standards, THF as eluent) is $M_n = 6,000$. ^1H NMR (DMF-d_7) confirms the following structure of the polymer:



5 b) aminolysis of trichloroethyl ester of poly-L-glutamic acid


1 g (3,8 mmole) of the above polymer is dissolved in 10 ml dry N,N-dimethylformamide. The solution is cooled down to 10°C and 0.69 ml (11,5 mmole) ethanolamine and 0.36 g (3,8 mmole) 2-hydroxypyridine are added. The reaction is followed by infrared spectroscopy. After the end of aminolysis, the resulting polymer is precipitated in ether, filtrated and dried under vacuum. It is then purified by gel filtration on Sephadex G-25 (water as eluent), isolated by lyophilization and characterised by ^1H NMR (D_2O) and GPC (dextran standards, water as eluent) as having a molecular weight $M_n = 4,500$. ^1H NMR analysis confirms the following structure of the polymer:



15 c) deprotection of triphenylmethyl group


1 g of the above polymer is dissolved in 10 ml trifluoroacetic acid and stirred at room temperature for 0,5 hour. Trifluoroacetic acid is removed by evaporation under vacuum. The resulting polymer is dissolved in water and centrifugated.

The supernatant is purified by gel filtration on Sephadex G-25 (water as eluent) and isolated by lyophilization. ¹H NMR (D₂O/DCI) analysis confirms the following structure of the polymer:



5 EXAMPLE 32 - synthesis of a PHEG derivative terminated with a carboxyl group and a disulfide group


1 g of the polymer of step (c) of example 31 (0.22 mmole) is dissolved in 50 ml N,N-dimethylformamide. 0.024 g succinic anhydride (0.24 mmole) and an equimolar amount of dimethylaminopyridine are added and the solution is stirred for 1 hour. Then the solvent is removed under vacuum and the residue is dissolved in water. The insoluble part is filtered off and the filtrate is purified by dialysis and lyophilized. ¹H NMR (D₂O) analysis confirms the following structure of the polymer:



15 EXAMPLE 33 - synthesis of PHEG terminated with an N-hydroxysuccinimide ester and a disulfide group

1 g of the polymer of example 32 (0.22 mmole) is dissolved in 30 ml N,N-dimethylformamide at 0°C. 0.05 g N-hydroxysuccinimide (0.44 mmole) is added under stirring followed by 0.09 g dicyclohexylcarbodiimide (0.44 mmole). The solution is left at room temperature and maintained under stirring for 4 hours,

after which the precipitated dicyclohexylurea is removed by filtration. The solvent is removed under vacuum and the product is triturated with ether, filtered and dried under vacuum.¹H NMR (DMF-d₇) analysis confirms the following structure of the polymer:



5 EXAMPLE 34 - coupling of a hetero bifunctional PHEG with superoxide dismutase

The polymer of example 33 is dissolved in 0.02 M borate buffer, pH 8.0 (10 mg/ml) and added to a solution of superoxide dismutase (SOD) in the same buffer (10 mg/ml). The solution is left for 1 hour at room temperature. The
10 resulting product is purified by using an Amicon ultrafiltration system with a PM-10 membrane and lyophilized. The degree of substitution, determined by TNBS, is 40 %. A schematic representation of the product is as follows: SOD~~PHEG~~S-S-Py.

EXAMPLE 35 - coupling of SOD~~PHEG~~S-S-Py with a RGD-peptide

15 The product of example 34 is dissolved in a 0.1 M phosphate buffer (10 mg/ml), pH 7.5. A RGD-peptide (HS-Cys-Gly-Arg-Gly-Asp-Ser-CONH₂) is dissolved in the same buffer (10 mg/ml, two-fold excess with respect to the S-S-Py moiety) and added to the above solution. The release of pyridine-2-thione, measured by ultraviolet spectroscopy, is used for determination of the end of
20 the reaction (about 1 hour). The product is purified by using an Amicon ultrafiltration system with a PM-10 membrane and lyophilized. A schematic representation of the product is as follows: SOD~~PHEG~~RGD-peptide

EXAMPLE 36 - synthesis of a PHEG derivative conjugated with a poly-L-lysine (PLL-g-PHEG) and covalently bound to a RGD-peptide

25 a) coupling of NHS~~PHEG~~S-S-Py with poly-L-lysine

1 g poly-L-lysine ($M_n = 20,000$) is dissolved in 20 ml of a 0.1 M phosphate buffer pH 7.4. NHS--PHEG--S-S-Py (from 15.2) is dissolved in the same buffer and added to the solution. After stirring for 1 hr at room temperature, the mixture is separated on Sephadex G-25 (water as eluent). PLL-g-PHEG is isolated by lyophilization. ^1H NMR (D_2O) analysis shows 10 and 20 mol % grafted PHEG on the PLL chain.


b) coupling of PLL-g-PHEG--S-S-Py with an RGD-peptide

The above polymer PLL-g-PHEG--S-S-Py is dissolved in 0.1 M phosphate buffer (10 mg/ml), pH 7.5. A RGD-peptide (HS-Cys-Gly-Arg-Gly-Asp-Ser-CONH₂) is dissolved in the same buffer (10 mg/ml, two-fold excess with respect to the S-S-Py moiety) and added to the above solution. The release of pyridine-2-thione, measured by ultraviolet spectroscopy, is used for determining the end of the reaction (about 1 hour). The product is purified by using an Amicon ultrafiltration system with a PM-10 membrane and lyophilized. A schematic representation of the product is as follows: PLL-g-PHEG--RGD.

EXAMPLE 37 - synthesis of a block copolymer of poly- γ -hydroxyethyl-L-glutamine with polyglycolic acid


a) synthesis of polyglycolic acid with hydroxyl groups at both ends of the polymer chain

A silanized glass tube is charged with 1 g glycolide (9 mmole), 0.02 g 1,6-hexanediol (0.18 mmole) and two drops of stannous octoate. The tube is degassed, sealed under an argon blanket and placed in a thermostated oil bath at temperature 120-130°C. After 15 hours, polymerization is terminated by cooling to 4°C. The resulting polyglycolic acid (hereinafter referred to as PGA) is isolated by dissolving the reaction mixture in dichloromethane, followed by precipitation in hexane, then recrystallized from dichloromethane/methanol and dried under vacuum. Its molecular weight, determined by gel permeation chromatography using polystyrene standard and tetrahydrofuran as eluent, is $M_n = 10,000$ and its hydroxyl functionality, determined by ^1H NMR, is 2. ^1H NMR (CDCl_3) confirms the following structure of the polymer:



b) coupling of poly- γ -hydroxyethyl-L-glutamine with amino end group with polyglycolic acid

1 g polyglycolic acid obtained in step (a) is first activated, according to the scheme hereunder, by dissolving in 20 ml dichloromethane and adding 0.04 g carbonyldiimidazole (1.3 molar excess with respect to hydroxyl groups). The solution is stirred under reflux for 12 hours, then diluted with 20 ml dichloromethane and washed with water. The dichloromethane-layers are collected and dried over magnesium sulphate, the solvent is evaporated and the resulting product dried under vacuum.



^1H NMR (CDCl_3) confirms the above structure of the activated polymer.

c) coupling of activated PGA with PHEG- NH_2

1 g of the activated polymer prepared in step (b) is dissolved in 30 ml N,N-dimethylformamide. 0.97 g of the polymer of example 3 is dissolved in 40 ml N,N-dimethylformamide and added to the solution of activated PGA. The mixture is stirred at 60°C for 24 hours, then part of the solvent is removed under vacuum and the resulting product is precipitated in pentane, filtered and dried

under vacuum. The structure of the polymer (PHEG~~PGA~~PHEG) is confirmed by ^1H NMR (DMF-d_7) analysis.

EXAMPLE 38 - synthesis of a branched poly- γ -hydroxyethyl-L-glutamine


In this example, a modified L-lysine containing two primary amino groups
5 is used as an initiator for the polymerization of an N-carboxyanhydride of γ -hydroxyethyl-L-glutamate.

a) synthesis of a bifunctional modified L-lysine

This synthesis proceeds according to the scheme shown hereinafter. 1 g
L-lysine tertbutyl ester (4,9 mmole) is dissolved in 10 ml dichloromethane and
10 cooled to 0°C , then a solution of 3.5 g of a fluorenylmethyloxycarbonyl-protected 6-aminocaproic acid (9.8 mmole) in 20 ml dichloromethane is added. 2.02 g Dicyclocarbodiimide (9,8 mmole) is added and the solution is stirred for 1 hour at 0°C and overnight at room temperature. The precipitated dicyclohexylurea is filtered and the filtrate is precipitated in hexane. The
15 resulting product 3 (structure confirmed by ^1H NMR (CDCl_3) analysis) is filtered and dried under vacuum.


1 g of product 3 is dissolved in 10 ml N,N-dimethylformamide and 10 ml of a 10% solution of piperidine in N,N-dimethylformamide is added. After stirring for 1 hour at room temperature, the solvent is removed under vacuum and the
20 residue is triturated with ether, filtered and dried under vacuum. ^1H NMR (CDCl_3) analysis confirms the structure of product 4.

resulting polymer is isolated by filtration and dried under vacuum. Its molecular weight, determined by ^1H NMR (DMF-d_7), is $M_n = 10,500$. ^1H NMR (DMF-d_7) analysis confirms the following structure of the polymer:



c) aminolysis of a branched poly- γ -hydroxyethyl-L-glutamate with ethanolamine

5 Aminolysis of the branched poly- γ -hydroxyethyl-L-glutamate from step (b) is carried out and the product is isolated and characterised as already described in example 2. ^1H NMR (D_2O) analysis confirms the following structure of the polymer:




d) deprotection of the tert-butyl group on a branched poly- γ -hydroxyethyl-L-glutamine

10


1 g of the polymer obtained in step (b) is dissolved in 10 ml trifluoroacetic

acid and stirred at room temperature for 1 hour. Trifluoroacetic acid is removed under vacuum. The polymer is dissolved in water and centrifugated. The supernatant is purified by gel filtration on Sephadex G-25 (water as eluent), then the resulting product is isolated by lyophilization. ¹H NMR (D₂O) analysis confirms the following structure of the polymer:



EXAMPLE 39 - coupling of a branched poly-γ-hydroxyethyl-L-glutamine

The branched poly-γ-hydroxyethyl-L-glutamine obtained in example 38 can be coupled via its reactive carboxylic acid end group with a protein, peptide, enzyme (such as SOD) or cationic polymer containing amino groups while using the methods of examples 34 to 36. Schematic representations of products which can thus be obtained are as follows:





EXAMPLE 40 - synthesis of a branched poly-γ-hydroxyethyl-L-glutamine

This example illustrates the "activated monomer process" route followed by termination with a modified L-lysine, according to the scheme represented hereinafter.

2 g of an N-carboxyanhydride of γ-trichloroethyl-L-glutamate (TCEG-NCA) is dissolved in 20 ml dichloromethane. Solutions of 0.114 g N-acetylated

TCEG-NCA (5 mole % with respect to TCEG-NCA) in 5 ml dichloromethane and 0.06 g tributylamine (5 mole % with respect to TCEG-NCA) in 2 ml dichloroethane are then added to the solution of TCEG-NCA. After the end of the polymerization (about 3 hours), determined by infrared spectroscopy, a solution of 3.9 g of the modified L-lysine from example 38 in 5 ml dichloromethane is added and the reaction mixture is stirred for another 3 hours at room temperature. The solution is precipitated in pentane and the resulting polymer is isolated by filtration and dried under vacuum. Its molecular weight determined by ^1H NMR (DMF-d_7) is 12,000. ^1H NMR (DMF-d_7) confirms the structure of polymer 6 of the following scheme.






where R = (CH₂)₂-CO-NH-(CH₂)₂-OH

Aminolysis of the branched poly γ -hydroxyethyl-L-glutamate with ethanolamine is then carried out and the product is isolated and characterised as already described in Aminolysis of the branched poly example 2. ¹H NMR (D₂O) analysis confirms the above polymer structure.




- 5 Deprotection of the tert-butyl group on the branched poly- γ -hydroxyethyl-L-glutamine is performed as in example 38. ¹H NMR (D₂O) analysis confirms the following polymer structure:



1. A linear poly- α -amino-acid derivative having at least glutamic or aspartic or serinic repeating units and additionally having a functional group at one or both ends of the polymer backbone and/or only a single functional group as a side group on the polymer backbone, the said functional end group and/or side group being other than alcohol.
2. A linear poly- α -amino-acid derivative according to claim 1, wherein the said functional end group and/or side group is any reactive group, other than alcohol, that may be attached to either end of and/or be pending on the backbone of the said polymer containing at least glutamic or aspartic or serinic repeating units.
3. A linear poly- α -amino-acid derivative according to any of claims 1 and 2, wherein the said functional end group and/or side group is selected from amine, carboxyl, ester, carbonate, thiol, thiol precursor, thioisocyanate, thiocarbonate, urea, thiourea, aldehyde, acetal, N-carboxyanhydride, oxycarbonyl, maleimide or any vinyl group suitable for radical, anionic or cationic polymerization.
4. A linear poly- α -amino-acid derivative according to any of claims 1 to 3, wherein the glutamic or aspartic or serinic repeating units have the formula:
- $$-\text{CO}-\text{CHR}-\text{NH}- \quad (\text{I})$$
- wherein:
- R is defined as $-(\text{CH}_2)_n-\text{CO}-\text{OR}_1$ or $-(\text{CH}_2)_n-\text{CO}-\text{NHR}_2$ or CH_2OH ,
 - n is 1 or 2,
 - R_1 is selected from hydrogen, C_{1-20} alkyl, polyhalo C_{1-6} alkyl, aryl C_{1-6} alkyl and heteroaryl C_{1-6} alkyl, and
 - R_2 is C_{1-6} alkyl substituted with at least one alcohol group.

- 5
5. A linear poly- α -amino-acid derivative according to any of claims 1 to 4, additionally comprising repeating units of one or more comonomer(s) copolymerizable with the α -amino-acid sequence containing glutamic or aspartic or serinic repeating units.
6. A linear poly- α -amino-acid derivative according to claim 5, wherein the said co-monomer is any naturally occurring α -amino-acid other than glutamic acid, aspartic acid and serine.
- 10 7. A linear poly- α -amino-acid derivative according to claim 5, wherein the said co-monomer is a polymer block or sequence derived from ethylene oxide or propylene oxide or mixtures thereof or from a polyhydroxyalkanoate.

- 15 8. A linear multifunctional poly- α -amino-acid derivative according to any of claims 1 to 7, having any of the following formulae:







wherein:

- 25 - R is defined as $-(CH_2)_n-CO-OR_1$ or $-(CH_2)_n-CO-NHR_2$ or CH_2OH ,
 - n is 1 or 2,
 - R_1 is selected from hydrogen, C_{1-20} alkyl, polyhalo C_{1-6} alkyl, aryl C_{1-6} alkyl and heteroaryl C_{1-6} alkyl,
 - R_2 is C_{1-6} alkyl substituted with at least one alcohol group,
 30 - x or, where applicable, x + x' range from 2 to about 2,000, and
 - each of V and W independently represent a functional group, able to be attached to an end or on the side of the polymer

backbone containing the repeating units of formula (I),

- A is at least a co-monomer copolymerizable with the α -amino-acid sequence containing glutamic or aspartic or serinic repeating units,
- y ranges from 0 to about 500,
- T is a spacing unit selected from lysine and ornithine, and
- V' is a non-reactive end group.

9. A linear monofunctional poly- α -amino-acid derivative according to any of claims 1 to 7, having any of the following formulae:



wherein:

- R is defined as $-(CH_2)_n-CO-OR_1$ or $-(CH_2)_n-CO-NHR_2$ or CH_2OH ,
- n is 1 or 2,

- R_1 is selected from hydrogen, C_{1-20} alkyl, polyhalo C_{1-6} alkyl, aryl C_{1-6} alkyl and heteroaryl C_{1-6} alkyl,

- R_2 is C_{1-6} alkyl substituted with at least one alcohol group,

- x or, where applicable, $x + x'$ range from 2 to about 2,000, and
- each of V and W independently represent a functional group, able to be attached to an end or on the side of the polymer backbone containing the repeating units of formula (I),

- A is at least a co-monomer copolymerizable with the α -amino-acid sequence containing glutamic or aspartic or serinic repeating units,
- y ranges from 0 to about 500,

- T is a spacing unit selected from lysine and ornithine, and

- V' and W' are non-reactive end groups.

10. A linear poly- α -amino-acid derivative according to claim 8 or claim 9,

wherein A is represented by the formula $-CO-CHR'-NH-$ (III)


wherein R' is the side-chain group of an α -amino acid other than glutamic acid or aspartic acid or serine, or by the formula

$CH_2-CHR''-X'$ (IV) wherein:

- R'' is selected from hydrogen and methyl, and
 - X' is selected from a single bond and oxygen,
- or A is a repeating unit derived from a hydroxyalkanoate.

11. A linear poly- α -amino-acid derivative according to any of claims 8 to 10, wherein V' and/or W' is selected from C_{1-20} alkyl, $oxyC_{1-20}$ alkyl, aryl, aryl C_{1-20} alkyl, amide, heteroaryl and heteroaryl C_{1-20} alkyl.

12. A linear poly- α -amino-acid derivative according to claim 1, with at least one protective end group, being represented by the following formulae:




wherein:

- R is $-(CH_2)_n-CO-NHR_2$,
- n is 1 or 2,
- R₂ is C_{1-6} alkyl substituted with at least one alcohol group,
- x ranges from 2 to about 2,000,
- X₁ is $-R_4-Z_1-A_1$,
- each of R₃ and R₄ is independently selected from $(CH_2)_m$, arylene, C_{1-6} alkylarylene and aryl C_{1-6} alkylene,
- m is from 2 to 20,
- Y₁ is $-Z_2-A_2$, X₂ is $-R_4-Z_3-A_3$ or $-O-R_4-Z_3-A_3$,
- Y₂ is $-Z_4-A_4$,
- each of Z₁, Z₂, Z₃ and Z₄ is independently selected from NH, O, S, C(O)O, C(S)O, CO, CS, $-OCH-O-$ and $C=N-R_5$,

- each of A_1 , A_2 , A_3 and A_4 is a protective group suitable for Z_1 , Z_2 , Z_3 and Z_4 respectively, and
- R_5 is selected from hydrogen, C_{1-6} alkyl, aryl and C_{1-6} alkylaryl, heteroaryl and C_{1-6} alkylheteroaryl.

5

13. A linear poly- α -amino-acid derivative according to claim 1, being represented by the formula:





wherein:

- 10 - X_1 is $-R_4 - Z_1 - A_1$,
- R_4 is selected from $(CH_2)_m$, arylene, C_{1-6} alkylarylene and aryl C_{1-6} alkylene,
- x ranges from 2 to about 2,000,
- R is defined as $-(CH_2)_n - CO - OR_1$,
- n is 1 or 2,
- 15 - R_1 is selected from hydrogen, C_{1-20} alkyl, polyhalo C_{1-6} alkyl, aryl C_{1-6} alkyl and heteroaryl C_{1-6} alkyl,
- Z_1 is selected from NH, O, S, C(O)O, C(S)O, CO, CS, $-OCH-O-$ and $C = N - R_5$,
- A_1 is a protective group suitable for Z_1 , and
- 20 - R_5 is selected from hydrogen, C_{1-6} alkyl, aryl and C_{1-6} alkylaryl, heteroaryl and C_{1-6} alkylheteroaryl.

14. A linear poly- α -amino-acid derivative according to claim 1, being represented by any of the formulae:

25



and (XI),

wherein:

- R is $-(CH_2)_n-CO-NHR_2$,
- n is 1 or 2,
- 5 - R_2 is C_{1-6} alkyl substituted with at least one alcohol group,
- x ranges from 2 to about 2,000,
- X_1 is $-R_4-Z_1-D_1$,
- each of R_3 and R_4 is independently selected from $(CH_2)_m$, arylene, C_{1-6} alkylarylene and aryl C_{1-6} alkylene,
- 10 - m is from 2 to 20,
- each of R_3-Y_1 and R_3-Y_2 may be a group including a vinyl terminal moiety,
- X_2 is $-R_4-Z_3-D_3$,
- each of Z_1 , Z_2 , Z_3 and Z_4 is independently selected from NH, O, S, C(O)O, C(S)O, CO, CS, -OCH-O- and $C=N-R_5$,
- 15 - each of D_1 , D_2 , D_3 and D_4 is independently selected from hydrogen, aryl, heteroaryl, succinimidyl, vinyl, C_{1-6} alkylcarbonyl,
- each of Z_1-D_1 , Z_2-D_2 , Z_3-D_3 and Z_4-D_4 may be independently selected from maleimidyl, disulfide, α -haloacetoxy and C_{1-6} alkyloxymethylsulfide, and
- R_5 is selected from hydrogen, C_{1-6} alkyl, aryl and C_{1-6} alkylaryl, heteroaryl and
- 20 C_{1-6} alkylheteroaryl.

15. A linear poly- α -amino-acid derivative according to claim 14, wherein D_1 is different from D_2 and D_3 is different from D_4 .

- 25 16. A process for making a linear poly- α -amino-acid derivative according to any of claims 1 to 15, including a step comprising polymerizing a monomer or mixture of monomers comprising at least the N-carboxy anhydride of an amino-acid selected from glutamic acid, aspartic acid, serine and oxygen-protected serine in the presence of an effective
- 30 amount of a multifunctional initiator containing at least one primary amino group and further containing at least another functional group selected from maleimide, thioisocyanate, thiocarbonate, urea, thiourea,

aldehyde, acetal, oxycarbonyl, vinyl (such as acrylate, methacrylate, acrylamide, methacrylamide and the like), ester, carbonate, thiol precursor, protected amine and protected carboxylic acid and/or in the presence of an effective amount of a bi-functional terminating reagent.

5

17. A process according to claim 16, wherein the multifunctional initiator is selected from amino-acid esters, α -amino- ω -diC₁₋₆alkylacetals, α, α' -diamino C₁₋₆alkyldisulfides and α -amino- ω -maleimido alkanonic acid amides.

10

18. A process according to claim 16 or claim 17, wherein the amount of the multifunctional initiator ranges between about 0.2 and 30 mole % with respect to the N-carboxy-anhydride monomer.

15

19. A process according to any of claims 16 to 18, wherein the amount of the bi-functional terminating reagent ranges between 2 and 5 equivalents with respect to the molar amount of the multifunctional initiator.

20

20. A process according to any of claims 16 to 19, further including aminolysis of the pending R₁ group of the glutamic, aspartic or serinic repeating unit by means of an effective amount of an amino-alcohol, in the presence of an effective amount of a reaction promoter.

25

21. A process according to claim 20, wherein the effective amount of the amino-alcohol used during the said aminolysis step ranges from 1 to 50, equivalents with respect to the monomeric units in the polymer.

30

22. A process according to claim 20 or claim 21, wherein the effective amount of the reaction promoter ranges from 0.5 to 5 equivalents with respect to the monomeric units in the polymer.

23. A process for making a linear poly- α -amino-acid derivative according to any of claims 1 to 15, including:

- a first step of N-acylating part of an α -amino-acid selected from glutamic acid, aspartic acid and serine, then separately treating the N-acylated α -amino-acid and the remaining part of the said α -amino-acid in order to form a mixture of the corresponding N-carboxy anhydrides, and
- a second step of copolymerizing the said mixture of N-carboxy anhydrides in the presence of an initiator.

24. A process according to claim 23, wherein the N-carboxy anhydride of the α -amino-acid is used in excess of the N-carboxy anhydride of the N-acylated α -amino-acid.

25. A process according to claim 23 or claim 24, wherein the N-carboxy anhydride-terminated polymer obtained in the second step is reacted with a reagent having the formula $H_2N - R_3 - Y_2$, wherein:

- R_3 is selected from $(CH_2)_m$, arylene, C_{1-6} alkylarylene and aryl C_{1-6} alkylene,
- Y_2 is $-Z_4-A_4$,
- Z_4 is selected from NH, O, S, C(O)O, C(S)O, CO, CS, -OCH-O- and $C=N-R_5$,
- A_4 is a protective group suitable for Z_4 , and
- R_5 is selected from hydrogen, C_{1-6} alkyl, aryl and C_{1-6} alkylaryl, heteroaryl and C_{1-6} alkylheteroaryl.

26. A biodegradable article containing a copolymer comprising at least a moiety derived from a poly- α -amino-acid derivative according to any of claims 1 to 15, provided that the functional group at one or both ends thereof is an unsaturated group.

27. Use of a poly- α -amino-acid derivative according to any of claims 1 to

15 for the modification of a biologically-active ingredient.

28. An enzymatically degradable poly- α -amino-acid derivative according to any of claims 1 to 15, containing a L-amino-acid sequence.

5

29. The product of coupling a poly- α -amino-acid derivative according to any of claims 1 to 15 with a biomolecule.

30. The product of claim 29, wherein the said biomolecule is a therapeutic agent, prophylactic agent, diagnostic agent, protein, peptide, hormone, antibody or fragment thereof, oligonucleotide, plasmid, DNA, interleukin, interferon, enzyme or fragment thereof.

10

31. The product of claim 29 or claim 30, being an antibody modified by means of the said functional poly- α -aminoacid derivatives and having a second functionality for hooking and/or being able to attach another targeting group such as an antibody, a peptide, an oligopeptide or a saccharide.

15

32. Use of a non degradable poly- α -amino-acid derivative according to any of claims 1 to 15, containing a D-amino-acid sequence, for the surface modification of a biomaterial.

20

33. A synthetic polymer for a polymer-based carrier vehicle or vector for delivery of DNA or other nucleic acid material to target cells in a biological system, comprising a linear poly- α -amino-acid derivative according to any of claims 1 to 15.

25

34. A synthetic polymer for a polymer-based carrier vehicle or vector according to claim 33, further comprising a synthetic vector component such as polyethyleneimine, poly-L-lysine, a star-shaped dendrimer or chitosan.

30

35. A method of treatment of a patient in need of such treatment, comprising

30

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 December 2000 (28.12.2000)

PCT

(10) International Publication Number
WO 00/78791 A3

- (51) International Patent Classification⁷: C08G 69/10, A61K 47/48
- (21) International Application Number: PCT/BE00/00066
- (22) International Filing Date: 19 June 2000 (19.06.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
99870125.4 17 June 1999 (17.06.1999) EP
- (71) Applicant (for all designated States except US): **UNIVERSITEIT GENT** [BE/BE]; St. Pietersnieuwstraat 25, B-9000 Gent (BE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **SCHACHT, Etienne, Honoré** [BE/BE]; Rysseveldstraat 99, B-8840 Staden (BE). **TONCHEVA, Veska** [BG/BE]; Pacificatielaan 5, B-9000 Gent (BE).
- (74) Agents: **BIRD, William** et al.; Bird Goën & Co., Vilvoordsebaan 92, B-3020 Winksele (BE).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report
- (88) Date of publication of the international search report:
13 December 2001
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*






(54) Title: FUNCTIONAL POLY- α -AMINOACID DERIVATIVES USEFUL FOR THE MODIFICATION OF BIOLOGICALLY ACTIVE MATERIALS AND THEIR APPLICATION

(57) Abstract: A linear poly- α -amino-acid derivative has at least glutamic or aspartic or serinic repeating units and additionally having a functional group at one or both ends of the polymer backbone and/or only a single functional group as a side group on the polymer backbone, the said functional end group and/or side group being other than alcohol. The said functional derivative is useful for the modification of biologically active materials.

WO 00/78791 A3

1/2


FIGURE 1



7

N-protected TCEG-NCA

2/2

FIGURE 2

SUBSTITUTE SHEET (RULE 26)

Attorney Docket No. 522-1767

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled FUNCTIONAL POLY-ALPHA-AMINOACID DERIVATIVES USEFUL FOR THE MODIFICATION OF BIOLOGICALLY ACTIVE MATERIALS AND THEIR USE the specification of which:

_____ is attached hereto.

X was filed on June 19, 2000 as

Application Serial No. PCT/BE00/00066 and

was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

PRIOR FOREIGN APPLICATION(S)

<u>Country</u>	<u>Number</u>	<u>Date Filed</u>	<u>Priority Claimed</u>	
			<u>Yes</u>	<u>No</u>
Europe	99870125.4	17 June 1999	X	

I hereby claim the benefit under Title 35, United States Code Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.


<u>Application Serial No.</u>	<u>Filing Date</u>	<u>Status</u>
PCT/BE00/00066	19 June 2000	Pending

And I hereby appoint Thomas E. Smith, Registration No. 18,243, Dennis M. McWilliams, Registration No. 25,195, James R. Sweeney, Registration No. 18,721, William M. Lee, Jr., Registration No. 26,935, Glenn W. Ohlson, Registration No. 28,455, David C. Brezina, Registration No. 34,128, Jeffrey R. Gray, Registration No. 33,391, Gerald S. Geren, Registration No. 24,528, Timothy J. Engling, Registration No. 39,970, Peter J. Shakula, Registration No. 40,808, Robert F. I. Conte, Registration No. 20,354, Howard B. Rockman, Registration No. 22,190, John W. Hayes, Registration No. 19,286, and Mark A. Hagedorn, Registration No.

~~44,731~~, to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith. It is requested that all communications be directed to Lee, Mann, Smith, McWilliams, Sweeney & Ohlson, P.O. Box 2786, Chicago, Illinois 60690-2786, telephone number (312) 368-1300.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: ETIENNE HONORÉ SCHACHT

Signature  Date 18.01.2002

Country of Residence: Belgium

Country of Citizenship: Belgium

Post Office and Residence Address: Rysseveldstraat 99
B-8840 Staden
Belgium



Full name of joint inventor: VESKA TONCHEVA

Signature  Date 18.01.2002

Country of Residence: Belgium

Country of Citizenship: Belgium

Post Office and Residence Address: Pacificatielaan 5
B-9000 Gent
Belgium

